A recent publication in Frontiers in Neurology, stemming from an international research collaboration with CSL, validated the significance of Brainomix's follow-up infarct volume (FIV) automated imaging biomarkers to predict clinical outcomes after acute ischemic stroke (AIS).

"CSL is proud to champion research which can improve and optimize clinical trial design. Working with partners like Brainomix, we are contributing to a better understanding of selection and endpoint markers in acute ischemic stroke, which in turn can improve the development of treatment for patients," Moshe Vardi, MD, Vice President, R&D Therapeutics Area Co-Lead at CSL.

"Brainomix has the most extensive and well validated suite of AI biomarkers in the field of stroke. It was a pleasure to collaborate on this important research, showing how Brainomix's quantitative AI imaging can improve patient characterization and outcome assessment in stroke clinical trials," Dr Waleed Brinjikji, Professor of Radiology & Neurosurgery, Mayo Clinic.

"We are excited to include Brainomix AI biomarkers in our TIPAL study. Brainomix technology has shown it can provide robust quantification of changes in fibrosis and disease status during ILD treatment, which will add greater data insights into our study," Prof Andrew Wilson, Chief Investigator, Clinical Professor, Norfolk and Norwich University Hospitals.

TIPAL is a multicenter clinical trial designed to find out if proton pump inhibitors (anti-acid drugs) are beneficial for people with idiopathic pulmonary fibrosis (IPF).

"The use of Brainomix's comprehensive suite of e-Lung biomarkers will unlock novel mechanistic insights into the potential utility of Lansoprazole in idiopathic pulmonary fibrosis. This collaboration on an NIHR-funded study reiterates Brainomix's commitment to research and to advancing the field for IPF patients across the globe," Dr Peter George, Brainomix Senior Medical Director.

Brainomix were featured alongside other leading AI innovators in an article by Inside Precision Medicine, focused on the impact of AI on clinical trials and the Life Science space generally.

"It was clinical trials that really drove the creation of Brainomix. Now, in addition to helping clinicians diagnose stroke and lung disease, we are continuing to support people running trials, both selecting suitable patient populations and biomarkers before trials begin, and in monitoring endpoints during the trials,” noted Dr George Harston, Chief Medical & Innovation Officer at Brainomix.

Read the full IPM article here.